Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal antibody (mAb) therapies. Immune responses to other viral antigens are generated after SARS-CoV-2 infection, but their contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dangi, Tanushree, Sanchez, Sarah, Class, Jacob, Richner, Michelle, Visvabharathy, Lavanya, Chung, Young Rock, Bentley, Kirsten, Stanton, Richard J., Koralnik, Igor J., Richner, Justin M., Penaloza-MacMaster, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711872/
https://www.ncbi.nlm.nih.gov/pubmed/36219482
http://dx.doi.org/10.1172/JCI162282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9711872/
https://www.ncbi.nlm.nih.gov/pubmed/36219482
http://dx.doi.org/10.1172/JCI162282

Ejemplares similares